ENDPOINTS

Bayer CEO Bill Anderson previews 2025 turnaround plans

Something changed for Bill Anderson when he turned 50. He was ascending the ranks of Roche’s Genentech, but the Texas native felt like he was stuck in the same loop year after year. The company ...

Feb 27, 2025 - 16:02
 0
Bayer CEO Bill Anderson previews 2025 turnaround plans
Something changed for Bill Anderson when he turned 50. He was ascending the ranks of Roche’s Genentech, but the Texas native felt like he was stuck in the same loop year after year. The company ...
Read More

Tags:

Previous Article

Four ways to power-up AI for drug discovery

Next Article

Cleveland Clinic’s AI Scribe Bake-Off: How Ambience Healthcare Came Out on Top

Related Posts

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Bluebird bio to sell to investment funds after struggli...

Feb 21, 2025  0

Bavarian Nordic wins FDA OK for chikungunya vaccine in challenge to Valneva 

Bavarian Nordic wins FDA OK for chikungunya vaccine in ...

Feb 18, 2025  0

States sue Trump administration over billions in NIH indirect cost cuts

States sue Trump administration over billions in NIH in...

Feb 10, 2025  0